quinine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4523 130-95-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quinine bisulfate heptahydrate
  • chinine
  • qualaquin
  • quinine
  • quinine sulfate
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
  • Molecular weight: 324.42
  • Formula: C20H24N2O2
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 45.59
  • ALOGS: -2.99
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O
1.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 111.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 12 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 71.07 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.30 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 80 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.066 Moderate 0.74
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.436 Moderate 0.74
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 18.408 10^-6 cm/s Moderate 0.74
dh-clint Dog hepatocyte intrinsic clearance 8.204 uL/min/10^6 cells Moderate 0.74
dppb Dog plasma protein binding (% unbound) 22.830 % Moderate 0.74
fcs-ppb Fetal calf serum protein binding (% unbound) 46.380 % Moderate 0.74
herg hERG pIC50 5.636 pIC50 Moderate 0.74
hh-clint Human hepatocyte intrinsic clearance 4.375 uL/min/10^6 cells Moderate 0.74
hlm-clint Human liver microsomal intrinsic clearance 35.400 uL/min/mg protein Moderate 0.74
hppb Human plasma protein binding (% unbound) 23.480 % Moderate 0.74
kinase-safety-class ACVR2B,AXL,CAMK2D,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC 10
kinase-selectivity-class AXL,CAMK2D,CDK9,EIF2AK3,MAP2K6 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 12.331 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 6.934 Moderate 0.74
mh-clint Mouse hepatocyte intrinsic clearance 75.336 Moderate 0.74
mppb Mouse plasma protein binding (% unbound) 22.340 Moderate 0.74
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 31.189 Moderate 0.74
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 38.630 % Moderate 0.74
rat-kpuu-brain Rat brain Kpuu 0.031 % High 1
rh-clint Rat hepatocyte intrinsic clearance 60.395 uL/min/10^6 cells Moderate 0.74
rh-fuinc Rat hepatocyte fraction unbound in incubation 66.510 % Moderate 0.74
rppb Rat plasma protein binding (% unbound) 27.870 % Moderate 0.74
solubility-dd Solubility at pH 7.4 in DMSO 849.180 uM Moderate 0.74

Approvals:

DateAgencyCompanyOrphan
Aug. 12, 2005 FDA MUTUAL PHARM CO INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 343.02 15.06 197 14878 82150 90531222
Labile blood pressure 178.28 15.06 45 15030 1865 90611507
Sedation complication 132.57 15.06 62 15013 16882 90596490
Lipase increased 126.81 15.06 53 15022 11058 90602314
Toxicity to various agents 116.30 15.06 187 14888 287659 90325713
Creatinine renal clearance decreased 111.41 15.06 57 15018 18842 90594530
Creatinine renal clearance increased 111.22 15.06 35 15040 3246 90610126
Renal function test abnormal 108.71 15.06 42 15033 7149 90606223
Cognitive disorder 108.63 15.06 91 14984 69316 90544056
Blood calcium decreased 98.97 15.06 62 15013 30120 90583252
Haematemesis 97.52 15.06 64 15011 33662 90579710
Hepatic ischaemia 90.94 15.06 22 15053 763 90612609
Somatic symptom disorder 89.38 15.06 30 15045 3411 90609961
Sacroiliitis 87.16 15.06 31 15044 4188 90609184
Hepatorenal syndrome 87.07 15.06 26 15049 2022 90611350
Orthostatic hypotension 85.09 15.06 64 15011 41763 90571609
Depressed level of consciousness 83.32 15.06 80 14995 72704 90540668
Coronary artery disease 74.12 15.06 54 15021 33569 90579803
Fall 73.00 15.06 210 14865 481600 90131772
Sedation 70.93 15.06 61 15014 48110 90565262
Hepatic failure 70.36 15.06 56 15019 39672 90573700
Multiple drug therapy 68.63 15.06 30 15045 6979 90606393
Renal failure 63.91 15.06 93 14982 130914 90482458
Thrombotic microangiopathy 63.64 15.06 37 15038 15706 90597666
Constipation 60.82 15.06 140 14935 280255 90333117
Muscle relaxant therapy 60.43 15.06 12 15063 161 90613211
Drug interaction 59.92 15.06 138 14937 276315 90337057
Coagulopathy 57.30 15.06 40 15035 23249 90590123
Hypotension 55.29 15.06 148 14927 325249 90288123
Gastrointestinal haemorrhage 54.44 15.06 71 15004 90177 90523195
Infusion related reaction 54.06 15.06 4 15071 416776 90196596
Hyponatraemia 52.77 15.06 86 14989 133452 90479920
Electrocardiogram QT prolonged 51.68 15.06 62 15013 72394 90540978
Balance disorder 48.91 15.06 70 15005 97010 90516362
Duodenal ulcer 48.28 15.06 26 15049 9526 90603846
Hypovolaemia 47.05 15.06 28 15047 12403 90600969
Drug ineffective 44.14 15.06 104 14971 1384194 89229178
Cinchonism 43.78 15.06 6 15069 3 90613369
Pancreatitis 43.77 15.06 56 15019 69770 90543602
Mood altered 43.48 15.06 30 15045 17114 90596258
Synovitis 43.22 15.06 3 15072 329749 90283623
Neoplasm skin 42.73 15.06 17 15058 3125 90610247
Drug intolerance 42.55 15.06 11 15064 447580 90165792
Hepatic enzyme increased 40.29 15.06 6 15069 360730 90252642
Fear of eating 39.43 15.06 10 15065 422 90612950
Coronary artery bypass 36.50 15.06 14 15061 2335 90611037
Post procedural haemorrhage 36.41 15.06 21 15054 8777 90604595
Acute kidney injury 35.89 15.06 126 14949 320261 90293111
Retinal toxicity 35.36 15.06 12 15063 1410 90611962
Hand deformity 35.32 15.06 4 15071 296358 90317014
Rheumatoid arthritis 34.28 15.06 9 15066 362605 90250767
Haemorrhoidal haemorrhage 34.13 15.06 17 15058 5306 90608066
Hiccups 33.07 15.06 14 15061 3012 90610360
Drug hypersensitivity 32.67 15.06 158 14917 463451 90149921
Myocardial ischaemia 32.29 15.06 23 15052 13791 90599581
Swollen tongue 32.23 15.06 39 15036 45917 90567455
Product dose omission issue 32.22 15.06 5 15070 291682 90321690
Blood sodium decreased 30.91 15.06 30 15045 27583 90585789
Abdominal discomfort 30.58 15.06 21 15054 477307 90136065
Rhabdomyolysis 30.39 15.06 40 15035 51216 90562156
Overdose 29.05 15.06 74 15001 157635 90455737
Abdominal rigidity 28.71 15.06 12 15063 2500 90610872
Nail infection 28.44 15.06 12 15063 2560 90610812
Fatigue 28.37 15.06 98 14977 1153925 89459447
Liver function test abnormal 27.58 15.06 38 15037 50807 90562565
Discomfort 27.51 15.06 6 15069 274329 90339043
Tarsal tunnel syndrome 27.48 15.06 8 15067 569 90612803
Purpura senile 26.98 15.06 8 15067 607 90612765
Vestibular disorder 26.85 15.06 10 15065 1539 90611833
Left ventricular dysfunction 26.65 15.06 21 15054 14648 90598724
Oral cavity fistula 26.62 15.06 8 15067 636 90612736
Vascular injury 26.17 15.06 9 15066 1101 90612271
Hepatocellular injury 26.12 15.06 28 15047 28930 90584442
Therapeutic product effect decreased 26.02 15.06 7 15068 277564 90335808
Cerebrovascular accident 25.98 15.06 61 15014 123472 90489900
Vulvovaginal mycotic infection 25.94 15.06 15 15060 6299 90607073
Cardiomegaly 25.90 15.06 23 15052 18902 90594470
Salivary gland enlargement 25.56 15.06 7 15068 399 90612973
Exostosis of jaw 25.00 15.06 9 15066 1258 90612114
Hypomagnesaemia 24.63 15.06 30 15045 35558 90577814
Oesophageal disorder 24.58 15.06 11 15064 2702 90610670
Cardiac arrest 24.49 15.06 54 15021 104881 90508491
Clostridium difficile colitis 24.40 15.06 26 15049 26680 90586692
Myocardial infarction 24.13 15.06 54 15021 105918 90507454
Exposed bone in jaw 23.79 15.06 11 15064 2915 90610457
Sinusitis 23.46 15.06 14 15061 343074 90270298
Poor peripheral circulation 23.31 15.06 12 15063 4013 90609359
Gastrointestinal disorder 23.08 15.06 7 15068 256680 90356692
Cerebral artery occlusion 22.71 15.06 8 15067 1051 90612321
Swelling 22.41 15.06 22 15053 419036 90194336
Pain 22.23 15.06 88 14987 996253 89617119
Optic ischaemic neuropathy 22.17 15.06 9 15066 1743 90611629
Hypersensitivity 21.95 15.06 26 15049 454651 90158721
Eczema asteatotic 21.89 15.06 6 15069 343 90613029
Off label use 21.76 15.06 102 14973 1102150 89511222
Resorption bone increased 21.61 15.06 8 15067 1211 90612161
Type 2 diabetes mellitus 21.30 15.06 4 15071 203240 90410132
Alopecia 21.15 15.06 31 15044 495040 90118332
Arthralgia 20.54 15.06 64 15011 778458 89834914
Muscle necrosis 20.51 15.06 7 15068 837 90612535
Multiple organ dysfunction syndrome 20.47 15.06 39 15036 68297 90545075
Nephrogenic systemic fibrosis 20.25 15.06 11 15064 4097 90609275
Gastritis 19.41 15.06 29 15046 41724 90571648
International normalised ratio increased 19.39 15.06 31 15044 47285 90566087
Hyperkalaemia 19.37 15.06 37 15038 64927 90548445
Intentional product use issue 19.34 15.06 6 15069 216886 90396486
Product use issue 19.21 15.06 16 15059 329903 90283469
Neuropathy peripheral 19.02 15.06 58 15017 136912 90476460
Transient ischaemic attack 18.67 15.06 29 15046 43147 90570225
Ulcer 18.47 15.06 25 15050 32857 90580515
Adrenal mass 18.36 15.06 7 15068 1148 90612224
Irritable bowel syndrome 18.04 15.06 6 15069 207442 90405930
Deep vein thrombosis 17.92 15.06 44 15031 91576 90521796
Nasopharyngitis 17.87 15.06 25 15050 407079 90206293
Hepatic cyst 17.85 15.06 12 15063 6556 90606816
Lethargy 17.65 15.06 35 15040 63104 90550268
Condition aggravated 17.11 15.06 47 15028 595498 90017874
Sequestrectomy 17.07 15.06 6 15069 783 90612589
Weight increased 17.04 15.06 27 15048 417900 90195472
Cardiac failure congestive 16.82 15.06 45 15030 98649 90514723
Intestinal ischaemia 16.75 15.06 13 15062 8870 90604502
Joint swelling 16.58 15.06 37 15038 503263 90110109
Arthropathy 16.56 15.06 22 15053 366220 90247152
Chest pain 16.41 15.06 100 14975 319545 90293827
Blood alkaline phosphatase increased 16.37 15.06 29 15046 48050 90565322
Disseminated intravascular coagulation 16.29 15.06 19 15056 21519 90591853
Peripheral vascular disorder 15.71 15.06 11 15064 6420 90606952
Exposure via ingestion 15.58 15.06 8 15067 2659 90610713
Hyponatraemic seizure 15.47 15.06 5 15070 505 90612867
Injection site pain 15.14 15.06 5 15070 173694 90439678

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1161.02 17.06 508 7778 104263 42508786
Toxicity to various agents 295.82 17.06 287 7999 228849 42384200
Poisoning 82.02 17.06 45 8241 14654 42598395
Cinchonism 62.74 17.06 9 8277 7 42613042
Exposure via ingestion 61.97 17.06 21 8265 2101 42610948
Compartment syndrome 46.10 17.06 19 8267 3270 42609779
Electrocardiogram U wave present 43.12 17.06 7 8279 21 42613028
Respiratory arrest 42.80 17.06 39 8247 28385 42584664
Intentional product misuse 42.26 17.06 56 8230 61844 42551205
Leg amputation 39.66 17.06 16 8270 2607 42610442
Retinal vascular disorder 39.27 17.06 9 8277 209 42612840
Drug ineffective 38.16 17.06 40 8246 630157 41982892
Unresponsive to stimuli 35.83 17.06 37 8249 31366 42581683
Off label use 34.87 17.06 44 8242 638291 41974758
Cardiac arrest 34.84 17.06 70 8216 109250 42503799
Atrioventricular block 34.14 17.06 22 8264 9593 42603456
Overdose 31.87 17.06 66 8220 105198 42507851
Miosis 31.85 17.06 24 8262 13422 42599627
Atrioventricular dissociation 31.35 17.06 7 8279 144 42612905
Urine sodium decreased 30.65 17.06 7 8279 160 42612889
Toxic neuropathy 30.31 17.06 9 8277 586 42612463
Nephrogenic systemic fibrosis 29.02 17.06 14 8272 3487 42609562
Lethargy 28.33 17.06 40 8246 46850 42566199
Mouth swelling 28.21 17.06 12 8274 2234 42610815
Agitated depression 27.10 17.06 7 8279 271 42612778
Hypomagnesaemia 26.26 17.06 30 8256 28458 42584591
Sedation complication 25.19 17.06 12 8274 2907 42610142
Prescription drug used without a prescription 22.88 17.06 11 8275 2719 42610330
Cerebral malaria 22.64 17.06 3 8283 0 42613049
Lower respiratory tract infection 21.77 17.06 33 8253 41173 42571876
Body mass index decreased 21.73 17.06 6 8280 301 42612748
Sinus bradycardia 21.61 17.06 20 8266 14833 42598216
Muscle spasms 21.54 17.06 50 8236 85994 42527055
Neuropsychiatric syndrome 21.17 17.06 5 8281 133 42612916
Confusional state 21.07 17.06 76 8210 167521 42445528
Blindness 20.17 17.06 21 8265 17957 42595092
Skin induration 19.99 17.06 9 8277 1918 42611131
Tendonitis 19.83 17.06 16 8270 9878 42603171
Infected skin ulcer 19.68 17.06 9 8277 1989 42611060
Cutaneous extramedullary haemopoiesis 19.34 17.06 3 8283 6 42613043
Retinal toxicity 18.53 17.06 6 8280 521 42612528
Increased bronchial secretion 18.30 17.06 9 8277 2337 42610712
Blood sodium decreased 18.23 17.06 20 8266 18142 42594907
Malaise 17.83 17.06 85 8201 212071 42400978
Lip swelling 17.45 17.06 20 8266 19033 42594016
Biliary ischaemia 17.29 17.06 4 8282 97 42612952

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1474.34 14.27 707 20767 176704 110391121
Toxicity to various agents 383.27 14.27 468 21006 480087 110087738
Thrombotic microangiopathy 181.62 14.27 96 21378 29053 110538772
Labile blood pressure 155.34 14.27 44 21430 2427 110565398
Sedation complication 151.57 14.27 75 21399 19780 110548045
Creatinine renal clearance increased 102.46 14.27 35 21439 3590 110564235
Renal function test abnormal 99.99 14.27 44 21430 8902 110558923
Cinchonism 96.47 14.27 14 21460 13 110567812
Creatinine renal clearance decreased 95.47 14.27 57 21417 21758 110546067
Blood calcium decreased 91.76 14.27 67 21407 35778 110532047
Cognitive disorder 87.37 14.27 96 21378 87415 110480410
Somatic symptom disorder 87.33 14.27 30 21444 3129 110564696
Haematemesis 83.05 14.27 78 21396 59030 110508795
Depressed level of consciousness 82.02 14.27 105 21369 112173 110455652
Poisoning 80.45 14.27 57 21417 29048 110538777
Sacroiliitis 77.49 14.27 31 21443 4947 110562878
Drug ineffective 77.45 14.27 110 21364 1520430 109047395
Hepatic ischaemia 77.39 14.27 22 21452 1229 110566596
Fall 73.10 14.27 270 21204 603212 109964613
Exposure via ingestion 71.06 14.27 29 21445 4871 110562954
Hyponatraemia 66.59 14.27 137 21337 217516 110350309
Hepatorenal syndrome 65.96 14.27 27 21447 4570 110563255
Orthostatic hypotension 63.23 14.27 71 21403 66178 110501647
Multiple drug therapy 60.35 14.27 30 21444 7984 110559841
Overdose 59.91 14.27 137 21337 233657 110334168
Muscle relaxant therapy 58.65 14.27 12 21462 160 110567665
Acute kidney injury 57.62 14.27 260 21214 635170 109932655
Cardiac arrest 53.42 14.27 118 21356 196635 110371190
Microangiopathic haemolytic anaemia 51.96 14.27 18 21456 1925 110565900
Drug interaction 50.14 14.27 211 21263 499972 110067853
Off label use 50.00 14.27 139 21335 1500046 109067779
Respiratory arrest 48.13 14.27 58 21416 58241 110509584
Product dose omission issue 47.57 14.27 4 21470 321778 110246047
Sedation 47.49 14.27 63 21411 69620 110498205
Retinal toxicity 46.81 14.27 16 21458 1643 110566182
Infusion related reaction 46.15 14.27 9 21465 381153 110186672
Coronary artery disease 44.59 14.27 62 21412 71628 110496197
Rhabdomyolysis 44.36 14.27 82 21392 120319 110447506
Hypomagnesaemia 43.34 14.27 56 21418 60314 110507511
Hepatic enzyme increased 42.34 14.27 6 21468 320886 110246939
Synovitis 41.65 14.27 3 21471 274089 110293736
Electrocardiogram QT prolonged 41.14 14.27 75 21399 108885 110458940
Coagulopathy 41.02 14.27 45 21429 40866 110526959
Unresponsive to stimuli 40.92 14.27 56 21418 63734 110504091
Renal failure 40.58 14.27 116 21358 226458 110341367
Neoplasm skin 39.86 14.27 17 21457 3187 110564638
Nephrogenic systemic fibrosis 39.73 14.27 20 21454 5463 110562362
Atrioventricular block 39.72 14.27 30 21444 16847 110550978
Agitated depression 39.38 14.27 11 21463 576 110567249
Intentional product misuse 38.68 14.27 82 21392 132822 110435003
Lethargy 38.65 14.27 67 21407 93509 110474316
Blood sodium decreased 38.16 14.27 42 21432 38277 110529548
Hepatic failure 37.70 14.27 56 21418 68683 110499142
Gastrointestinal haemorrhage 36.98 14.27 92 21382 165426 110402399
Contraindicated product administered 36.93 14.27 3 21471 248264 110319561
Fear of eating 35.91 14.27 10 21464 518 110567307
Duodenal ulcer 35.88 14.27 30 21444 19484 110548341
Swollen tongue 35.75 14.27 51 21423 60311 110507514
Mood altered 35.50 14.27 31 21443 21344 110546481
Compartment syndrome 35.48 14.27 19 21455 5891 110561934
Balance disorder 35.18 14.27 73 21401 116487 110451338
Hypovolaemia 35.13 14.27 31 21443 21643 110546182
Rheumatoid arthritis 34.36 14.27 8 21466 299605 110268220
Constipation 34.31 14.27 149 21325 357637 110210188
Retinal vascular disorder 33.65 14.27 9 21465 400 110567425
Liver function test abnormal 33.35 14.27 53 21421 68897 110498928
Myocardial ischaemia 33.30 14.27 33 21441 26651 110541174
Blindness 33.04 14.27 38 21436 36321 110531504
Drug intolerance 32.96 14.27 19 21455 406493 110161332
Treatment failure 32.60 14.27 7 21467 277227 110290598
Electrocardiogram U wave present 31.84 14.27 7 21467 134 110567691
Prescription drug used without a prescription 31.13 14.27 17 21457 5479 110562346
Exposed bone in jaw 30.88 14.27 15 21459 3796 110564029
Fatigue 30.02 14.27 128 21346 1215830 109351995
Leg amputation 29.44 14.27 15 21459 4203 110563622
Hypotension 29.37 14.27 188 21286 523661 110044164
Pericarditis 29.12 14.27 4 21470 219110 110348715
Hand deformity 29.02 14.27 4 21470 218502 110349323
Post procedural haemorrhage 28.83 14.27 24 21450 15488 110552337
Haemorrhoidal haemorrhage 27.47 14.27 18 21456 8075 110559750
Therapeutic product effect decreased 27.08 14.27 7 21467 244309 110323516
Nail infection 27.04 14.27 12 21462 2476 110565349
Tarsal tunnel syndrome 26.65 14.27 8 21466 541 110567284
Cerebrovascular accident 26.08 14.27 86 21388 181198 110386627
Vulvovaginal mycotic infection 26.02 14.27 15 21459 5362 110562463
Purpura senile 25.76 14.27 8 21466 607 110567218
Myocardial infarction 24.90 14.27 88 21386 191995 110375830
Diastolic dysfunction 24.75 14.27 20 21454 12384 110555441
Toxic neuropathy 24.70 14.27 9 21465 1114 110566711
Atrioventricular dissociation 24.69 14.27 7 21467 387 110567438
Bradycardia 24.39 14.27 76 21398 155441 110412384
Vascular injury 24.33 14.27 9 21465 1162 110566663
Duodenal ulcer perforation 24.20 14.27 3 21471 177697 110390128
Exostosis of jaw 23.87 14.27 9 21465 1226 110566599
Sinusitis 23.85 14.27 14 21460 296674 110271151
Salivary gland enlargement 23.49 14.27 7 21467 462 110567363
Miosis 23.47 14.27 25 21449 21958 110545867
Hypocalcaemia 23.42 14.27 44 21430 65322 110502503
Melaena 23.05 14.27 45 21429 68712 110499113
Cerebral malaria 22.64 14.27 3 21471 0 110567825
Weight increased 22.59 14.27 29 21445 419615 110148210
Abdominal rigidity 22.57 14.27 12 21462 3668 110564157
Intentional product use issue 22.46 14.27 10 21464 247896 110319929
Cardiomegaly 22.45 14.27 28 21446 29102 110538723
International normalised ratio increased 22.36 14.27 51 21423 86721 110481104
Lip swelling 21.87 14.27 37 21437 50630 110517195
Oesophageal disorder 21.67 14.27 11 21463 3059 110564766
Poor peripheral circulation 21.09 14.27 12 21462 4185 110563640
Cardiovascular disorder 21.04 14.27 24 21450 22736 110545089
Oral cavity fistula 20.86 14.27 7 21467 680 110567145
Skin induration 20.58 14.27 12 21462 4383 110563442
Pyrexia 20.06 14.27 98 21376 898167 109669658
Hiccups 20.05 14.27 18 21456 12851 110554974
Type 2 diabetes mellitus 19.79 14.27 5 21469 177227 110390598
Blindness transient 19.61 14.27 13 21461 5943 110561882
Coronary artery bypass 19.44 14.27 13 21461 6029 110561796
Neuropsychiatric syndrome 18.79 14.27 5 21469 218 110567607
Left ventricular dysfunction 18.78 14.27 23 21451 23470 110544355
Resorption bone increased 18.62 14.27 8 21466 1526 110566299
Product use issue 18.42 14.27 20 21454 311675 110256150
Injection site pain 18.06 14.27 6 21468 177916 110389909
Restless legs syndrome 17.92 14.27 23 21451 24603 110543222
Irritable bowel syndrome 17.64 14.27 5 21469 164210 110403615
Vestibular disorder 17.33 14.27 9 21465 2623 110565202
Inappropriate schedule of product administration 17.24 14.27 9 21465 203628 110364197
Loss of personal independence in daily activities 17.20 14.27 4 21470 150016 110417809
Biliary ischaemia 16.81 14.27 4 21470 110 110567715
Nasopharyngitis 16.70 14.27 32 21442 394329 110173496
Cerebral artery occlusion 16.67 14.27 8 21466 1972 110565853
Discomfort 16.06 14.27 11 21463 214696 110353129
Optic ischaemic neuropathy 16.00 14.27 10 21464 4137 110563688
Eczema asteatotic 15.91 14.27 6 21468 818 110567007
Hallucination, visual 15.88 14.27 28 21446 39577 110528248
Body mass index decreased 15.82 14.27 6 21468 830 110566995
Sequestrectomy 15.82 14.27 6 21468 830 110566995
Ulcer 15.41 14.27 29 21445 43087 110524738
Peripheral vascular disorder 15.38 14.27 13 21461 8563 110559262
Swelling 15.29 14.27 28 21446 351013 110216812
Hypersensitivity 15.24 14.27 35 21439 403963 110163862
Stomatitis 15.24 14.27 18 21456 270224 110297601
General physical health deterioration 15.13 14.27 38 21436 425257 110142568
Clostridium difficile colitis 15.10 14.27 29 21445 43749 110524076
Plasmodium falciparum infection 15.09 14.27 4 21470 172 110567653
Deafness 14.98 14.27 22 21452 26687 110541138
Mouth swelling 14.97 14.27 12 21462 7342 110560483
Febrile neutropenia 14.96 14.27 24 21450 316743 110251082
Cardio-respiratory arrest 14.94 14.27 53 21421 115783 110452042
Gastrointestinal disorder 14.88 14.27 15 21459 241937 110325888
Condition aggravated 14.80 14.27 83 21391 734753 109833072
Therapy non-responder 14.80 14.27 6 21468 157301 110410524
Transient ischaemic attack 14.74 14.27 36 21438 63946 110503879
Sinus bradycardia 14.72 14.27 23 21451 29460 110538365
Arthralgia 14.67 14.27 90 21384 779542 109788283
Blood creatine phosphokinase increased 14.63 14.27 39 21435 73038 110494787
Night sweats 14.54 14.27 4 21470 133979 110433846
Hepatocellular injury 14.44 14.27 31 21443 50611 110517214
Muscle necrosis 14.34 14.27 7 21467 1790 110566035
Neutrophil count decreased 14.32 14.27 3 21471 120938 110446887
Bladder disorder 14.32 14.27 14 21460 11123 110556702
Urticaria 14.28 14.27 25 21449 318832 110248993

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M09AA72 MUSCULO-SKELETAL SYSTEM
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
Quinine and derivatives
ATC P01BC01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Methanolquinolines
FDA EPC N0000175482 Antimalarial
MeSH PA D000700 Analgesics
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000962 Antimalarials
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:51371 muscle relaxant

Related Drugs by ATC class:

M09AA Quinine and derivatives 1 drug
hydroquinine
P01BC Methanolquinolines 1 drug
mefloquine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Falciparum malaria indication 62676009 DOID:14067
Chloroquine Resistant Plasmodium Falciparum Malaria indication
Babesiosis off-label use 21061004 DOID:9643
Atrial flutter contraindication 5370000
Torsades de pointes contraindication 31722008
End stage renal disease contraindication 46177005 DOID:784
Atrial fibrillation contraindication 49436004 DOID:0060224
Neuromuscular block, function contraindication 55394004
Black water fever contraindication 56625005 DOID:14068
Acute nephropathy contraindication 58574008
Optic neuritis contraindication 66760008 DOID:1210
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Myasthenia gravis contraindication 91637004 DOID:437
Hemolytic uremic syndrome contraindication 111407006 DOID:12554
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.44 acidic
pKa2 8.02 Basic
pKa3 4.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.57 IUPHAR
Potassium voltage-gated channel subfamily H member 2 Ion channel WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 4.92 CHEMBL
Hemoglobin subunit alpha Secreted WOMBAT-PK
Potassium voltage-gated channel subfamily B member 2 Ion channel BLOCKER IC50 4.90 IUPHAR
Solute carrier family 22 member 1 Transporter IC50 4.29 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.36 CHEMBL

External reference:

IDSource
D08460 KEGG_DRUG
6183-68-2 SECONDARY_CAS_RN
6119-70-6 SECONDARY_CAS_RN
4018620 VANDF
4019926 VANDF
CHEBI:15854 CHEBI
QI9 PDB_CHEM_ID
CHEMBL170 ChEMBL_ID
CHEMBL2146083 ChEMBL_ID
CHEMBL2359966 ChEMBL_ID
2510 IUPHAR_LIGAND_ID
DB00468 DRUGBANK_ID
A7V27PHC7A UNII
647128 RXNORM
5023 MMSL
5405 MMSL
84102 MMSL
d00366 MMSL
002934 NDDF
002935 NDDF
373497008 SNOMEDCT_US
47065008 SNOMEDCT_US
47857006 SNOMEDCT_US
C0034417 UMLSCUI
D011803 MESH_DESCRIPTOR_UI
3034034 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-3002 CAPSULE 324 mg ORAL ANDA 30 sections
Qualaquin HUMAN PRESCRIPTION DRUG LABEL 1 13310-153 CAPSULE 324 mg ORAL NDA 32 sections
QUALAQUIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-595 CAPSULE 324 mg ORAL NDA 32 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 50742-238 CAPSULE 324 mg ORAL ANDA 29 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 65162-811 CAPSULE 324 mg ORAL ANDA 19 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 68180-560 CAPSULE 324 mg ORAL ANDA 20 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 68180-560 CAPSULE 324 mg ORAL ANDA 20 sections